For the month ended 30 April 2026, BioDlink International Company Limited maintained a stable capital structure, with no change in its issued share count or treasury shares. The company closed April with 772.79 million ordinary shares in issue, identical to the balance at the end of March.

Public float remained compliant with Hong Kong Main Board Rule 13.32D(1), confirming that at least 25% of BioDlink’s share class continues to be held by the public.

Within the Pre-IPO Share Option Scheme adopted on 20 February 2013 (exercise price: US $0.286, approximately HK$2.2335 per share), 7.61 million options were cancelled during the month. Post-cancellation, 20,000 options remain outstanding, representing the maximum number of shares that could still be issued under this scheme. No new options were granted or exercised, and no treasury shares were transferred.

Consequently, there were: • Zero new ordinary shares issued. • Zero treasury shares outstanding or cancelled. • No funds raised from option exercises in April.

All corporate actions were authorised by the board and executed in accordance with applicable listing rules and regulatory requirements, as confirmed by Joint Company Secretary Lui Wing Yat Christopher.